Description

XOMA 629 (formerly known as XMP.629) is a synthetic peptide derived from bactericidal/permeability-increasing protein (BPI), a human host-defense protein that is one of the body’s early lines of defense against invading microorganisms. Consistent with XOMA’s multi-indication approach to product development, we are currently evaluating XOMA 629 topically for the eradication of Staphylococcus aureus (staph), both sensitive and methicillin-resistant (MRSA), and superficial skin infections, such as impetigo.

Along with an alarming rise in antibiotic resistance, treatment of topical bacterial infections has become more complex. Physicians are increasingly relying on broad spectrum antimicrobials. In preclinical studies, XOMA 629 has been shown to act as a broad-spectrum antimicrobial. XOMA 629 has an encouraging safety profile based on clinical experience in 300 patients.

XOMA intends to commence clinical trials in 2008 to evaluate the safety and anti-microbial activity of XOMA 629 for use in superficial infections.

Publications and Presentations